Below you will find all our press releases. Simply click on the year that interests you to view the documents.

2018

Nov. 26 - Neptune to Participate in Fall 2018 Investor ConferencesNov. 13 - Neptune Announces Second Quarter ResultsOct. 31 - Neptune to Hold Conference Call to Discuss Second Quarter Results for the Three Months Period Ended September 30, 2018 Laval,Sept. 27 - Appointment of Caroline Lavoie and Evidence package submitted to Health CanadaSept. 20 - Neptune to Present at Sidoti & Company Fall 2018 ConferenceSept. 19 - Neptune Confirms its Name Change to Neptune Wellness Solutions Inc.Sept. 17 - Neptune Receives Confirmation of Readiness Letter from Health CanadaAug. 16 - Neptune Announces Appointment of Hélène F. Fortin to its Board of DirectorsAug. 15 - Neptune Announces the Election of its Directors and Voting ResultsAug. 14 - Neptune Announces First Quarter ResultsAug. 9 - Cannabis Patent ApplicationsJul. 31 - Neptune to Hold Conference Call to Discuss First Quarter Results Ended June 30th, 2018Jun. 19 - Neptune Announces Multi-year Agreement with Canopy Growth to Provide Extracted Cannabis ProductsJun. 5 - Neptune Announces Fourth Quarter and Year-end ResultsMar. 31 - Neptune to Hold Conference Call to Discuss Fourth Quarter and Fiscal Year-End Results Ended March 31, 2018Feb. 14 - Neptune Announces Third Quarter ResultsFeb. 12 - Neptune and Tetra Bio-Pharma Enter Co-Development Agreement for Purified Cannabinoid Oil-Based Products targeting Pain and InflammationJan. 31 - Neptune to Hold Conference Call to Discuss Third Quarter Results for the Interim Period Ended December 31, 2017Jan. 19 - Neptune Announces Research Agreement Aimed at New Medical and Wellness Cannabinoid-based ProductsJan. 17 - Neptune makes its recommendations on Bill 157 special consultations at the National Assembly

2017

Strength Sensei Nutraceuticals and Charles R. Poliquin launch MaxSimil®Neptune Receives Nasdaq Notification Confirming that it has Regained Compliance with Minimum Bid RequirementsHighlights of Neptune’s Investor Conference Being Held in New York TodayNeptune Extends Global MaxSimil® Licence To Cannabis-Derived ProductsNeptune Announces Second Quarter ResultsNeptune to Hold Business Update Meeting on November 28, 2017Neptune to Hold Conference Call to Discuss Second Quarter Results for the Interim Period Ended September 30, 2017Neptune announces appointments for its Cannabis BusinessNeptune Announces Resignation of Pierre Fitzgibbon as a Director and the Appointment of John Moretz as ChairmanNeptune to Hold Conference Call to Discuss the Transaction with Aker BioMarineAker BioMarine and Neptune announce closing of $US34 million transaction to accelerate business and industry developmentNeptune Receives Nasdaq Notification Regarding Minimum Bid RequirementsNeptune to Hold Conference Call to Discuss First Quarter Results for the Three Months Period Ended June 30, 2017Neptune Announces 4-Month Period and 13-Month Period ResultsNeptune to Hold Conference Call to Discuss Fourth Quarter and Fiscal Year-End Results for the Thirteen Months Period Ended March 31, 2017Unique Medical Cannabis Partnership Announced, Creating Scientific and Business Development Hub in Sherbrooke, QuebecNeptune enters into Commercial Distribution Joint Venture in China with Shanghai Chonghe Marine Industry Co., Ltd.Neptune and Enzymotec Reach Patent Agreement Ending All Litigation

2016

2015

2014

Neptunes Production Ramp-up on TargetNeuroBioPharm Announces Resignation of Chief Financial OfficerNeuroBioPharm Extends Life of Warrants and Provides Other Corporate UpdatesRodman & Renshaw 1st oneRodman & Renshaw 2nd oneNeptune, Acasti and NeuroBioPharm Announce Resignation of Chief Executive OfficerNeptune, Acasti and NeuroBioPharm Announce Litigation Regarding its Former Chief Executive OfficerNeptune to Hold Conference Call to Discuss First Quarter ResultsNeptune to Hold Conference Call to Discuss Fourth Quarter and Fiscal Year ResultsNeptune to Hold Conference Call to Discuss Second Quarter ResultsNeptune to Hold Conference Call to Discuss Third Quarter ResultsNeptune to Present at Rodman & Renshaw Global Investment ConferenceNeptune, Acasti and NeuroBioPharm Announce Appointment of Interim CEONeptune and BlueOcean Sign Licensing AgreementNeptune and Enzymotec Conclude Final Patent Infringement Settlement and License AgreementNeptune and Acasti Provide Update on Patent Litigations with EnzymotecNeptune Announces Proposed Offering of Common SharesNeptune Announces Proposed Director Nominees for its Upcoming Annual General MeetingNeptune Announces Pricing of US$25 million Offering of Common SharesNeptune Announces Normal Course Issuer BidNeptune Announces Fourth Quarter and Fiscal Year ResultsNeptune Announces First Quarter ResultsNeptune Announces Closing of the Over-Allotment Option Associated with its Recently Completed Public Offering of Common SharesNeptune Announces Closing of US$25.0 Million Underwritten Offering of Common SharesNeptune Announces Closing of CAD$2.5 Million Private PlacementNeptune & Acasti Give Update on Patent Litigations with EnzymotecNeptune Announces Second Quarter Results Shipments of NKO UnderwayNeptune Appoints John Moretz as Special Advisor and Nominee to its Board of DirectorsNeptune Completes Plant Ramp-UpNeptune Sherbrooke Plant to Resume Production Product Line ExpandedNeptune Responds to Enzymotecs Continuous Attempts to Shift Focus from ITC InvestigationNeptune Reports Third Quarter Results and Provides Update on Action Plan to Resume OperationsNeptune Reports Results of Annual and Special MeetingNeptune Receives New Food Raw Material Certification in ChinaNeptune Receives Composition Patent in AustraliaNeptune Obtains New US Patent Relating to Treatment of AlzheimersNeptune Provides Update on Plant Operating PermitsNeptune Provides Update on Sherbrooke PlantNeptune Reaches Annualized Production Capacity of 100 Metric TonsNeptune Receives CSST ReportJim Hamilton Appointed President & CEO of Neptune

2013

Neptune to Hold Conference Call 09-05-2013Neptune files ITC Complaint against competitors Aker, Enzymotec, Rimfrost, Olympic and othersNeptune and Rimfrost Sign Krill Oil Manufacturing and Supply AgreementNeptune and Aker BioMarine Reach Patent Infringement Settlement And License AgreementNeptune to Hold Conference CallNeptune to Oppose CSST StatementNeptune to Present at JMP Securities Healthcare ConferenceNeptune to Present at the Annual ROTH ConferenceNeptune, Acasti and Enzymotec Sign Settlement Term Sheet Resulting in Stay of ITC Investigation for 30 DaysPatent Infringement Settlements Reached Neptune Grants a Royalty Bearing License on its PatentsReed V. Tuckson, M.D. Joins Neptunes Board of DirectorsThe U.S. International Trade Commission (ITC) Votes to Institute Patent Infringements Investigation based on Neptune & Acasti ComplaintNeptune Responds to Akers Continued Attempts to Deflect Attention from its Sustained Patent InfringementNeptune Responds to Aker BioMarines Attempt to Shift the Focus from Neptunes Major ITC FilingNeptune Reports Third Quarter Results and Confirms First Insurance PaymentClass Action Lawsuit Against Neptune DismissedFirst Quarter Results and Update on Action PlanNeptune Announces Issuance of SharesNeptune Appoints Jerald J. Wenker as Special Advisor and Nominee to Its Board of DirectorsNeptune Awarded Canadian Composition of Matter PatentNeptune Commences Reconstruction of Sherbrooke PlantNeptune Holds Annual Charity Poker Game to Benefit Vitamin AngelsNeptune Obtains Allowance of Patent Specific to Krill Oil And Announces Management ReorganizationNeptune Obtains a Third U.S. Patent on Phospholipid Compositions, Further Bolstering Neptunes Request for an ITC InvestigationNeptune Participates in the Equity Financing of Acasti PharmaNeptune Provides Update on European Patent Dispute and Maintains its International Patent StrategyNeptune Reaffirms its Patent PositionNeptune Receives $12.5 Million Loan Offer from Investissement QuÇbecNeptune Receives Additional $5 million Insurance PaymentNeptune Reports Fiscal 2013 Results and Provides Update on Action Plan to Resume OperationsNeptune Reports Second Quarter Results and Provides Update on Action Plan to Resume OperationsNeptune to Hold Conference Call to Discuss Second Quarter ResultsNeptune to Hold Conference Call to Discuss First Quarter ResultsNeptune to Hold Conference Call details

2012

Neptune Technologies & Bioressources investing over $20M in SherbrookeNeptune Signs John Elway, NFL Hall-of-Famer, as Official Brand AmbassadorNeptune Secures Another U.S. PatentNeptune Reports Third Quarter ResultsNeptune Reports Second Quarter ResultsNeptune Reports Preliminary Revenues on Second QuarterNeptune Reports Preliminary Revenues on First QuarterNeptune Reports Fiscal 2012 ResultsNeptune Reports First Quarter ResultsNeptune To Hold Conference CallNeptune is Actively Working on Action PlanRoyalty Prepayment Agreement with AcastiOpposition of Akers Australian PatentNeptunes Competitor Claims an Illusory VictoryNeptunes Board of Director Welcomes Dr. Harlan WaksalNeptunes Allowance of Continuation of 348 Patent Strengthens Its Position in the U.S.Neptune, the Only Krill Oil Manufacturer Certified as Friend of the SeaNeptune, Aker and Schiff Agree to Stay of Litigation during Patent Re-examination ProceedingsNeptune to Present at The 24th Annual Roth ConferenceNeptune to Hold Conference Call 30-05-2012Neptune Pursues its IP Strategy with Continuation ApplicationsNeptune Premium Krill Oil, NKO Enters the Mass Market with Jamieson Laboratories, the Largest Brand in CanadaNeptune Acquires Common Shares of Acasti PharmaNeptune & Acasti Reappoint The Howard Group as Investor Relations ConsultantNKO Ambassador John Elway to Speak at SupplySide MarketPlace (NYC) and to Visit Neptunes BoothERRATUM Neptune To Hold Conference CallECO Krill Oil Specifications SheetConference Call for Post IncidentAction Plan Post IncidentASIAN Market Exceptional Growth Boosting Neptunes Sales2012-11-12 Neptune Press Release ExplosionNeptune Announces Dividend-In-Kind and Record Date for Partial Spin-Off of NeuroBioPharm IncNeptune Announces Pricing of US$30 million Offering of Common SharesNeptune Must Again Rectify Competitors Misleading StatementNeptune Krill Oil Specifications SheetNeptune Files a Second Patent Infringement Suit Against Competitors Aker, Enzymotec, and OthersNeptune Dismisses Akers Inaccurate Allegations About Its New PatentNeptune Confirms its Pre-eminence in the Australian MarketNeptune Confirms Dividend Ratio for Partial Spin-Off of NeuroBioPharm IncNeptune Believes the Australian Patent Office Will Reconsider its Grant of Akers Australian PatentNeptune Appoints New IR firm for the USNeptune Announces Proposed Offering of Common Shares2012-11-05 Poker tournament

2011

Neptunes customer is awarded Product of the Year 2011 in DenmarkNeptune subscirbes to Acasti Pharmas rights offeringNeptune reaffirms its confidence in its patent protection and the US prosecution processNeptune penetrates Asia by partnering with Chinese SKFC, the worlds largest fleet owner of fishing VesselsNeptune is Nominated as a Finalist for the Nutraceutical & Business Technology Awards 2011 and Prolongs US IR AgreementNeptune Technologies & Bioressources Common Shares Graduate to the TSXNeptune Technologies & Bioressources Confirms Dividend of Acasti RightsNeptune Technologies & Bioressources Environmental Responsibility and Business Conduct Acknowledged by NSF InternationalNeptune Technologies & Bioressources Inc. Reports Net Profit for the Third QuarterNeptune Technologies & Bioressources Inc. subsidiary Acasti Pharma Inc. Shares to Trade on the TSX-Venture on March 31stNeptune Technologies & Bioressources Inc. to Host Management Discussion Teleconference at 9 am on January 14thNeptune Technologies & Bioressources Inc. to Present at the Roth OC Growth Stock ConferenceNeptune Technologies & Bioressources Inc. welcomes Dr. Anthony Holler to its Board of DirectorsNeptune Technologies & Bioressources Obtains New Patent Directed to Compositions of Omega-3 Fatty Acid Phospholipids including Krill OilNeptune Technologies & Bioressources Secures an additional $2.865MNeptune To Hold Conference CallNeptune Technologies & Bioressources Closes Oversubscribed Private Placement FinancingNeptune Technologies & Bioressources Announces the Inssuance of an Additional Key US PatentNeptune Technologies & Bioressources Announces a Private Placement Financing of Approximately $10 Million USDBayer Healthcares Artic Wonder Market Test Succeeds with Neptune Krill Oil Leading to US National LaunchNeptune Launches Patent Infringement Litigation against Aker Biomarine ASA, Enzymotec Ltd., and OthersNeptune Receives TSX Conditional ApprovalNeptune Reports First Quarter ResultsNeptune Reports Fiscal 2011 ResultsNeptune Reports Preliminary Revenues on Record QuarterNeptune Reports Second Quarter ResultsNeptune Reports on Preliminary 2011 Year End ResultsNeptune Secures and Increases US Food, Drug, Mass and Club DistributionNeptune Starts Phase-I Sherbrooke Plant ExpansionNeptune Stronger in Asia by Penetrating the Indian Market

2010